Skip to main content
  • Site Staff Website Access Request Form
  • Connect With Us
  • Login

Search form

Home
  • About BMT CTN
    • What We Do
    • Why We Do What We Do
    • Who’s Involved
    • Clinical Centers
    • Enrollment in BMT CTN Studies
    • Our Annual Progress Report
    • Publications
    • State of the Science Symposia
    • Our History
    • Study Summaries for Patients
  • BMT CTN Studies
  • Investigator & Research Staff Resources
    • Overview
    • Administrative Manual of Procedures (MOP)/Policy Guidelines
    • Center Membership & Study Participation
    • Resources for Research Coordinators
    • Correlative Study Proposals
    • Funding Opportunities
    • Technical and Administrative Committees
    • Author Resources
  • Partner With Us

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

TitleA refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
Publication TypeJournal Article
Year of Publication2015
AuthorsMacMillan, ML, Robin, M, Harris, AC, DeFor, TE, Martin, PJ, Alousi, A, Ho, VT, Bolaños-Meade, J, Ferrara, JLM, Jones, R, Arora, M, Blazar, BR, Holtan, SG, Jacobsohn, D, Pasquini, M, Socie, G, Antin, JH, Levine, JE, Weisdorf, DJ
JournalBiol Blood Marrow Transplant
Volume21
Issue4
Pagination761-7
Date Published2015 Apr
ISSN1523-6536
KeywordsAcute Disease, Adolescent, Adult, Aged, Allografts, Child, Child, Preschool, Disease-Free Survival, Female, Graft vs Host Disease, Hematologic Neoplasms, Humans, Infant, Male, Middle Aged, Risk Factors, Stem Cell Transplantation, Survival Rate
Abstract

To develop a novel acute graft-versus-host disease (GVHD) risk score, we examined the GVHD clinical stage and grade of 1723 patients at the onset of treatment with systemic steroids. Using clinical grouping, descriptive statistics and recursive partitioning, we identified poorly responsive, high-risk (HR) acute GVHD by the number of involved organs and severity of GVHD at onset. The overall response (complete response/partial response) rate 28 days after initiation of steroid therapy for acute GVHD was lower in the 269 patients with HR-GVHD than in the 1454 patients with standard risk (SR)-GVHD (44% [95% confidence interval (CI) 38% to 50%] versus 68% [95% CI, 66% to 70%], P

DOI10.1016/j.bbmt.2015.01.001
Alternate JournalBiol Blood Marrow Transplant
PubMed ID25585275
PubMed Central IDPMC4359643
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
UG1 HL069286 / HL / NHLBI NIH HHS / United States
P30 CA077598 / CA / NCI NIH HHS / United States
U10 HL069290 / HL / NHLBI NIH HHS / United States
U10 HL069330 / HL / NHLBI NIH HHS / United States
U10 HL069310 / HL / NHLBI NIH HHS / United States
U10HL069290 / HL / NHLBI NIH HHS / United States
U10 HL109526 / HL / NHLBI NIH HHS / United States
P30 CA016672 / CA / NCI NIH HHS / United States
UL1 TR002494 / TR / NCATS NIH HHS / United States
P01 CA065493 / CA / NCI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
U10 HL069286 / HL / NHLBI NIH HHS / United States
U10 HL069249 / HL / NHLBI NIH HHS / United States
U10 HL069334 / HL / NHLBI NIH HHS / United States
U10 HL109137 / HL / NHLBI NIH HHS / United States
2P01CA065493 / CA / NCI NIH HHS / United States
  • Google Scholar
  • PubMed
  • DOI

Blood & Marrow Transplant Clinical Trials Network (BMT CTN)

Blood and Marrow Transplant Clinical Trials Network Twitter

Copyright © 2023, The Emmes Company LLC